Fig. 2From: Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control studySubgroup analysis of OS at 24 months in phase 2 treated patients (N = 55). aNumber of subjects at risk at Month 24. bAssessed after bridging therapy and prior to KTE-X19 infusion. CNS = central nervous system. LCI = lower confidence interval. OS = overall survival; SCT = stem cell transplant. UCI = upper confidence intervalBack to article page